Macrocycles as factor XIa inhibitors

US10487086B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10487086-B2
Application numberUS-201715718431-A
CountryUS
Kind codeB2
Filing dateSep 28, 2017
Priority dateFeb 11, 2010
Publication dateNov 26, 2019
Grant dateNov 26, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein: ring A is independently a C 3-10 carbocycle; ring B is pyridazine; ring C is independently a benzene ring or a 5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NH, N(C 1-4 alkyl), O, and S(O) p ; L 1 is independently selected from the group consisting of: a bond, —CHR 5 —, —CHR 5 CHR 5 —, —CR 5 ═CR 5 —, —C≡C—, —OCH 2 —, —CHR 5 NH—, —CH 2 O—, —SCH 2 —, —SO 2 CH 2 —, —CH 2 NH—, and —CR 5 R 5 —; L is independently selected from the group consisting of: C 3-8 alkylene, C 3-8 alkenylene, and C 4-8 alkynylene; wherein said alkylene, alkenylene and alkynylene are substituted with 0-2 R 7 and optionally one or more of the carbon atoms of said alkylene and alkenylene may be replaced by O, S, NH, N(C 1-4 alkyl), CO, CONH, NHCO, OCONH, NHCO 2 ,—NHCONH—, SO 2 NH, NHSO 2 , CON(C 1-4 alkyl), or N(C 1-4 alkyl)CO; Y is independently selected from the group consisting of: CH 2 , CH(C 1-4 alkyl), C(C 1-4 alkyl) 2 , CO, O, S, NH, N(C 1-4 alkyl), N(CO 2 (C 1-4 alkyl)), —N(C 1-4 alkyl)CH 2 —, —N(CO 2 (C 1-4 alkyl))CH 2 —, —N(CH 2 CO 2 (C 1-4 alkyl))CH 2 —, —CONH—, —NHCO—, —CONHCH 2 —, —CON(C 1-4 alkyl)CH 2 —, —OCONH—, —OCON(C 1-4 alkyl)-, —NHCONH—, —SO 2 NH—, —NHCO 2 —, and —NHSO 2 —; alternatively, L-Y is —C 3-6 alkylene-CH═N—; R 1 is, independently at each occurrence, selected from the group consisting of: halogen, C 1-6 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 haloalkyl, OH, OCH 2 F, OCHF 2 , OCF 3 , CN, NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , CO 2 (C 1-4 alkyl), CO(C 1-4 alkyl), —CH 2 NH 2 , —CONH 2 , —CONH(C 1-4 alkyl), —OCH 2 CO 2 H, —NHCO(C 1-4 alkyl), —NHCO 2 (C 1-4 alkyl), —NHSO 2 (C 1-4 alkyl), —SO 2 NH 2 , —C(═NH)NH 2 , and phenyl substituted with 0-2 R a ; R 2 is independently a 5- to 7-membered heterocycle comprising carbon atoms and 1-4heteroatoms selected from N, NH, N(C 1-4 alkyl), O, and S(O) p , wherein said heterocycle is substituted with 0-2 R 2a ; R 2a is, independently at each occurrence, selected from the group consisting of: halogen, C 1-4 alkyl, —CH 2 OH, C 1-4 alkoxy, OH, CF 3 , OCF 3 , CN, NH 2 , CO 2 H, CO 2 (C 1-4 alkyl), COC 1-4 alkyl, —CONH 2 , —CONH(C 1-4 alkyl), —CON(C 1-4 alkyl) 2 , —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —SO 2 NH(C 1-4 alkyl), and —SO 2 N(C 1-4 alkyl) 2 ; R 3 is independently selected from the group consisting of: H, ═O, halogen, OH, NH 2 , CN, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, —CH 2 OH, CO 2 H, CO 2 (C 1-4 alkyl), —C(O)NH 2 , —C(O)NH(C 1-4 alkyl), —C(O)N(C 1-4 alkyl) 2 , —CH 2 CO 2 H, and C 3-6 cycloalkyl; R 4 is independently selected from the group consisting of: H, and C 1-4 alkyl; R 5 is, independently at each occurrence, selected from the group consisting of: H, halogen, OH, and C 1-4 alkyl; R 6 is, independently at each occurrence, selected from the group consisting of: halogen, C 1-4 alkyl, CN, OH, CF 3 , CO 2 H, CO 2 (C 1-4 alkyl), —CH 2 CO 2 H, —(CH 2 ) 2 CO 2 H, —CH 2 CO 2 (C 1-4 alkyl), —(CH 2 ) 2 CO 2 (C 1-4 alkyl), NH 2 , —CH 2 NH 2 , —NHCO(C 1-4 alkyl), —NHCOCF 3 , —NHCO 2 (C 1-4 alkyl), —NHCO 2 (CH 2 ) 2 O(C 1-4 alkyl), —NHCO 2 (CH 2 ) 3 O(C 1-4 alkyl), —NHCO 2 CH 2 CH(C 1-4 alkyl)O(C 1-4 alkyl), —NHCO 2 (CH 2 ) 2 OH, —NHCO 2 (CH 2 ) 2 NH 2 , —NHCO 2 (CH 2 ) 2 N(C 1-4 alkyl) 2 , —NHCO 2 CH 2 CO 2 H, —CH 2 NHCO 2 (C 1-4 alkyl), —NHC(O)NH(C 1-4 alkyl), —NHC(O)N(C 1-4 alkyl) 2 , —NHSO 2 (C 1-4 alkyl), —SO 2 NH 2 , —SO 2 NH(C 1-4 alkyl), —SO 2 NH(CH 2 ) 2 OH, —SO 2 NH(CH 2 ) 2 O(C 1-4 alkyl), —CONH 2 , —CONH(C 1-4 alkyl), —CON(C 1-4 alkyl) 2 , —CH 2 CONH 2 , and —NHCO 2 (CH 2 ) 0-2 R 9 ; R 7 is, independently at each occurrence, selected from the group consisting of: halogen, OH, NH 2 , CH 2 NH 2 , C 1-4 haloalkyl, OCH 2 F, OCHF 2 , OCF 3 , —NH(C 1-4 alkyl), —N(C 1-4 alkyl) 2 , C 1-4 alkoxy, CH 2 OH, CH 2 O(C 1-4 alkyl), CH 2 O(CH 2 ) 1-4 O(C 1-4 alkyl), CO 2 H, CO 2 (C 1-4 alkyl), CO 2 (CH 2 ) 2 O(C 1-4 alkyl), CO 2 (C 1-4 haloalkyl), CO 2 (CH 2 ) 2 SO 2 (C 1-4 alkyl), CH 2 CO 2 H, CH 2 CO 2 (C 1-4 alkyl), CONH 2 , CONH(C 1-4 alkyl), CON(C 1-4 alkyl) 2 , —OCO(C 1-4 alkyl), —CH 2 NH(CH 2 ) 2 O(C 1-4 alkyl), —CONH(C 1-4 alkoxy), —CO 2 (CH 2 ) 2 O(C 1-4 alkyl), —CO 2 (CH 2 ) 2 N(C 1-4 alkyl) 2 , —CONH(CH 2 ) 2 O(C 1-4 alkyl), —CONH(CH 2 ) 2 N(C 1-4 alkyl) 2 , —CON(C 1-4 alkyl)(CH 2 ) 2 O(C 1-4 alkyl), —CON(C 1-4 alkyl)(CH 2 ) 2 N(C 1-4 alkyl) 2 , C 1-4 alkyl, —CONHBn, —CONH(OBn), —(CO) 0-1 (CH 2 ) 0-3 —C 3-6 carbocycle, and —(CH 2 ) 0-1 —(CO) 0-1 —(W) 0-1 -(CH 2 ) 0-2 —(4- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NH, N(C 1-4 alkyl), O, and S(O) p ); wherein said carbocycle and heterocycle are substituted with 0-2 R 8 ; R 8 is, independently at each occurrence, selected from the group consisting of: halogen, OH, CHF 2 , CF 3 , C 1-4 alkoxy, CH 2 OH, CO 2 H, CO 2 (C 1-4 alkyl), CONH 2 , and C 1-4 alkyl; R 9 is a 4- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NH, N(C 1-4 alkyl), N(CO 2 (C 1-4 alkyl)), O, and S(O) p ; R a is, independently at each occurrence, selected from the group consisting of: halogen, OH, CF 3 , C 1-4 alkoxy, and C 1-4 alkyl; W is independently selected from the group consisting of: O, NH and N(C 1-4 alkyl); and p is, independently at each occurrence, selected from the group consisting of: 0, 1, and 2. 2. The compound of claim 1 , wherein: ring A is independently a 6-membered carbocycle or a 9- to 10-membered carbocycle; and ring C is benzene. 3. The compound of claim 2 , wherein: ring A is benzene. 4. The compound of claim 1 , wherein: L 1 is independently selected from the group consisting of: a bond, —CH 2 CH 2 —, —CH═CH—, —C(Me)═CH—, —C≡C—, and —CH 2 NH— in Formula (I); L is independently selected from the group consisting of: C 3-7 alkylene and C 3-7 alkenylene; wherein said alkylene and alkenylene are substituted with 0-2 R 7 and optionally one or two of the carbon atoms of said alkylene and alkenylene may be replaced by O, CO, NH, N(C 1-4 alkyl), CONH, NHCO, or CON(C 1-4 alkyl); Y is independently selected from the group consisting of: CH 2 , CO, CH(C 1-4 alkyl), C(C 1-4 alkyl) 2 , O, S, NH, N(C 1-4 alkyl), N(CO 2 (C 1-4 alkyl)), —N(C 1-4 alkyl)CH 2 —, —N(CO 2 (C 1-4 alkyl))CH 2 —, —N(CH 2 CO 2 (C 1-4 alkyl))CH 2 —, —CONH—, —NHCO—, —CONHCH 2 —, —CON(C 1-4 alkyl)CH 2 —, —OCONH—, —NHCONH—, and —SO 2 NH—; alternatively, L-Y is —(CH 2 ) 3-6 —CH═N—; R 1 is, independently at each occurrence, selected from: halogen, CN, OH, OCH 2 F, OCHF 2 , OCF 3 , C 1-4 haloalkyl, C 1-4 alkyl, C 1-4 alkoxy, CO(C 1-4 alkyl), NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , —C(═NH)NH 2 , —C(O)NH 2 , —CH 2 NH 2 , and —SO 2 NH 2 ; R 3 is independently selected from the group consisting of: H, halogen, OH, NH 2 , CN, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, —CH 2 OH, CO 2 H, CO 2 (C 1-4 alkyl), C(O)NH 2 , —C(O)NH(C 1-4 alkyl), —C(O)N(C 1-4 alkyl) 2 , —CH 2 CO 2 H, and C 3-6 cycloalkyl; and R 6 is, independently at each occurrence, selected from the group consisting of: halogen, C 1-4 alkyl, CN, OH, CF 3 , CO 2 H, CO 2 (C 1-4 alkyl), —CH 2 CO 2 H, —(CH 2 ) 2 CO 2 H, —CH 2 CO 2 (C 1-4 alkyl), —(CH 2 ) 2 CO 2 (C 1-4 alkyl), NH 2 , —CH 2 NH 2 , —NHCO(C 1-4 alkyl), —NHCO 2 (C 1-4 alkyl), —NHCO 2 (CH 2 ) 2 O(C 1-4 alkyl), —NHCO 2 (CH 2 ) 3 O(C 1-4 alkyl), —NHCO 2 CH 2 CH(C 1-4 alkyl)O(C 1-4 alkyl), —NHCO 2 (CH 2 ) 2 OH, —NHCO 2 (CH 2 ) 2 NH 2 , —NHCO 2 CH 2 CO 2 H, —CH 2 NHCO 2 (C 1-4 alkyl), —NHC(O)NH(C 1-4 alkyl), —NHC(O)N(C 1-4 alkyl) 2

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10487086B2 cover?
The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compound…
Who is the assignee on this patent?
Bristol Myers Squibb Co
What technology area does this patent fall under?
Primary CPC classification C07D487/06. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).